These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32800944)

  • 41. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
    Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression.
    Shi C; Yang EJ; Liu Y; Mou PK; Ren G; Shim JS
    Oncogene; 2021 Feb; 40(5):937-950. PubMed ID: 33293694
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.
    Garcia PL; Miller AL; Kreitzburg KM; Council LN; Gamblin TL; Christein JD; Heslin MJ; Arnoletti JP; Richardson JH; Chen D; Hanna CA; Cramer SL; Yang ES; Qi J; Bradner JE; Yoon KJ
    Oncogene; 2016 Feb; 35(7):833-45. PubMed ID: 25961927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs.
    Liu Z; Wei P; Yang Y; Cui W; Cao B; Tan C; Yu B; Bi R; Xia K; Chen W; Wang Y; Zhang Y; Du X; Zhou X
    Clin Cancer Res; 2015 Apr; 21(7):1752-63. PubMed ID: 25762344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms.
    Shi X; Mihaylova VT; Kuruvilla L; Chen F; Viviano S; Baldassarre M; Sperandio D; Martinez R; Yue P; Bates JG; Breckenridge DG; Schlessinger J; Turk BE; Calderwood DA
    Proc Natl Acad Sci U S A; 2016 Aug; 113(31):E4558-66. PubMed ID: 27432991
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
    Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
    Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selective BET-bromodomain inhibition by JQ1 suppresses dendritic cell maturation and antigen-specific T-cell responses.
    Remke N; Bisht S; Oberbeck S; Nolting J; Brossart P
    Cancer Immunol Immunother; 2021 Jan; 70(1):107-121. PubMed ID: 32651619
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Arsenic sulfide amplifies JQ1 toxicity via mitochondrial pathway in gastric and colon cancer cells.
    Tan Z; Zhang X; Kang T; Zhang L; Chen S
    Drug Des Devel Ther; 2018; 12():3913-3927. PubMed ID: 30532520
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer.
    Parizadeh SM; Jafarzadeh-Esfehani R; Fazilat-Panah D; Hassanian SM; Shahidsales S; Khazaei M; Parizadeh SMR; Ghayour-Mobarhan M; Ferns GA; Avan A
    IUBMB Life; 2019 Jul; 71(7):802-811. PubMed ID: 31116909
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The BET-Bromodomain Inhibitor JQ1 synergized ABT-263 against colorectal cancer cells through suppressing c-Myc-induced miR-1271-5p expression.
    Wu Z; Hu Z; Han X; Li Z; Zhu Q; Wang Y; Zheng Q; Yan J
    Biomed Pharmacother; 2017 Nov; 95():1574-1579. PubMed ID: 28950657
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment with Lingqi capsules suppresses colorectal cancer by inhibiting the hepatocyte growth factor/c‑Met signal transduction pathway.
    Wang GS; Zhao JL; Li H
    Mol Med Rep; 2015 Mar; 11(3):1865-70. PubMed ID: 25373931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TGF-β Negatively Regulates CXCL1 Chemokine Expression in Mammary Fibroblasts through Enhancement of Smad2/3 and Suppression of HGF/c-Met Signaling Mechanisms.
    Fang WB; Mafuvadze B; Yao M; Zou A; Portsche M; Cheng N
    PLoS One; 2015; 10(8):e0135063. PubMed ID: 26252654
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement.
    Sengupta S; Biarnes MC; Clarke R; Jordan VC
    Breast Cancer Res Treat; 2015 Apr; 150(2):265-78. PubMed ID: 25721606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
    Zanellato I; Colangelo D; Osella D
    Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SOX9 in prostate cancer is upregulated by cancer-associated fibroblasts to promote tumor progression through HGF/c-Met-FRA1 signaling.
    Qin H; Yang Y; Jiang B; Pan C; Chen W; Diao W; Ding M; Cao W; Zhang Z; Chen M; Gao J; Zhao X; Qiu X; Guo H
    FEBS J; 2021 Sep; 288(18):5406-5429. PubMed ID: 33705609
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
    Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
    Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BET inhibitor JQ1 suppresses cell proliferation via inducing autophagy and activating LKB1/AMPK in bladder cancer cells.
    Li F; Yang C; Zhang HB; Ma J; Jia J; Tang X; Zeng J; Chong T; Wang X; He D; Guo P
    Cancer Med; 2019 Aug; 8(10):4792-4805. PubMed ID: 31250978
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.
    Galimi F; Torti D; Sassi F; Isella C; Corà D; Gastaldi S; Ribero D; Muratore A; Massucco P; Siatis D; Paraluppi G; Gonella F; Maione F; Pisacane A; David E; Torchio B; Risio M; Salizzoni M; Capussotti L; Perera T; Medico E; Di Renzo MF; Comoglio PM; Trusolino L; Bertotti A
    Clin Cancer Res; 2011 May; 17(10):3146-56. PubMed ID: 21447729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.